Michael Hudecek, MD, University of Würzburg, Würzburg, Germany, gives an overview of the EBMT-EHA 4th European CAR T-cell Meeting program, highlighting the aims and importance of this meeting. Chimeric antigen receptor T-cell (CAR-T) therapy is one of the most rapidly evolving fields in translational research. The EBMT-EHA CAR T-cell meeting brings key opinion leaders (KOLs) and stakeholders from all over the world together to discuss the latest data in CAR-T therapies and exchange ideas to further improve this practice-changing technology. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.